Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Epigenetic modifications and regulators represent potential molecular elements which control relevant physiological and pathological features, thereby contributing to the natural history of human disease. These epigenetic modulators can be employed as disease biomarkers, since they show several advantages and provide information about gene function, thus explaining differences among patient endophenotypes. In addition, epigenetic biomarkers can incorporate information regarding the effects of the environment and lifestyle on health and disease, and monitor the effect of applied therapies. Technologies used to analyze these epigenetic biomarkers are constantly improving, becoming much easier to use. Laboratory professionals can easily acquire experience and techniques are becoming more affordable. A high number of epigenetic biomarker candidates are being continuously proposed, making now the moment to adopt epigenetics in the clinical laboratory and convert epigenetic marks into reliable biomarkers. In this review, we describe some current promising epigenetic biomarkers and technologies being applied in clinical practice. Furthermore, we will discuss some laboratory strategies and kits to accelerate the adoption of epigenetic biomarkers into clinical routine. The likelihood is that over time, better markers will be identified and will likely be incorporated into future multi-target assays that might help to optimize its application in a clinical laboratory. This will improve cost-effectiveness, and consequently encourage the development of theragnosis and the application of precision medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011) · Nature Cell Biology · doi:10.1038/ncb2210 · Cited by 2,741
Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells
Kosaka, N., Iguchi, H., Yoshioka, Y., Takeshita, F., Matsuki, Y., & Ochiya, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.107821 · Cited by 1,934
Multitarget Stool DNA Testing for Colorectal-Cancer Screening
Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Levin, T. R., Lavin, P., Lidgard, G. P., Ahlquist, D. A., & Berger, B. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311194 · Cited by 1,900 · cited 1×
“As described above, it detects promoter CpG islands (NDRG4 and BMP3) and 7 KRAS mutations in Exon 2 (accounting for 98% of KRAS mutations) with an ELISA immunoassay to detect human hemoglobin (FIT) as previously reported [93,94].”
BackgroundGiacona, M. B., Ruben, G. C., Iczkowski, K. A., Roos, T. B., Porter, D. M., & Sorenson, G. D. (1998) · Pancreas · doi:10.1097/00006676-199807000-00012 · Cited by 387
Plasma processing conditions substantially influence circulating microRNA biomarker levels
Cheng, H. H., Yi, H. S., Kim, Y., Kroh, E. M., Chien, J. W., Eaton, K. D., Goodman, M. T., Tait, J. F., Tewari, M., & Pritchard, C. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064795 · Cited by 317
Shah, J. S., Soon, P. S., & Marsh, D. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153200 · Cited by 216 · cited 1×
“[76] was found to be the most sensitive method to detect low levels of hemolysis, and should be included in the assay during miRNA analysis as quality control [77].”
MethodEpigenetic Research in Neuropsychiatric Disorders: the “Tissue Issue”
Bakulski, K. M., Halladay, A., Hu, V. W., Mill, J., & Fallin, M. D. (2016) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-016-0083-4 · Cited by 127 · cited 1×
“wide array of diseases and disorders, going beyond cancer, to include obesity and metabolic diseases [79], male infertility [80], neuropsychiatric disorders [81], etc.”
Background
Cited by
Epigenetics in health and disease
Zhang, L., Lu, Q., & Chang, C. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3449-2_1 · Cited by 689
Clinical epigenetics: seizing opportunities for translation
Berdasco, M., & Esteller, M. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0074-2 · Cited by 498
Biomarkers in Psychiatry: Concept, Definition, Types and Relevance to the Clinical Reality
García-Gutiérrez, M. S., Navarrete, F., Sala, F., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00432 · Cited by 331
Marine Environmental Epigenetics
Eirin-Lopez, J. M., & Putnam, H. M. (2019) · Annual Review of Marine Science · doi:10.1146/annurev-marine-010318-095114 · Cited by 286
Blood DNA methylation signatures to detect dementia prior to overt clinical symptoms
Fransquet, P. D., Lacaze, P., Saffery, R., Phung, J., Parker, E., Shah, R., Murray, A., Woods, R. L., & Ryan, J. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12056 · Cited by 36
Metadata
- Authors
- García-Giménez, J. L., Seco-Cervera, M., Tollefsbol, T. O., Romá-Mateo, C., Peiró-Chova, L., Lapunzina, P., & Pallardó, F. V.
- Venue
- Critical Reviews in Clinical Laboratory Sciences
- Publisher
- Informa UK Limited
- Published
- 2017-11-17
- Volume
- 54
- Issue
- 7-8
- Pages
- 529-550
- ISSN
- 1040-8363 (ISSN-L)
- 1549-781X
- OpenAlex
- W2774549795
- Cited by
- 170
- References
- 7
- FWCI
- 0.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory. https://app.cochat.ai/papers/10.1080/10408363.2017.1410520
- The paper
- García-Giménez, J. L., Seco-Cervera, M., Tollefsbol, T. O., Romá-Mateo, C., Peiró-Chova, L., Lapunzina, P., & Pallardó, F. V. (2017). Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory. Critical Reviews in Clinical Laboratory Sciences. https://doi.org/10.1080/10408363.2017.1410520
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.